Zithowin SF Kit is a combination pharmaceutical formulation containing Fluconazole 150 mg, Azithromycin 1 gm, and Secnidazole 1 gm, designed for the effective management of mixed infections caused by susceptible fungal, bacterial, and protozoal pathogens. Fluconazole, a triazole antifungal agent, inhibits fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, disrupting ergosterol synthesis and thereby compromising fungal cell membrane integrity. Azithromycin, a macrolide antibiotic, exerts its antibacterial activity by binding to the 50S ribosomal subunit, inhibiting bacterial protein synthesis and exhibiting broad-spectrum efficacy against gram-positive and certain gram-negative bacteria. Secnidazole, a nitroimidazole derivative, targets anaerobic protozoa and bacteria by inducing DNA strand breaks and inhibiting nucleic acid synthesis. The combined action of these agents makes Zithowin SF Kit suitable for treating complex infections such as mixed bacterial and fungal infections, sexually transmitted infections, and protozoal infections where monotherapy may be inadequate. This fixed-dose combination should be used under medical supervision with consideration of patient history, potential drug interactions, and contraindications. Adherence to prescribed dosage and duration is essential to maximize therapeutic outcomes and minimize resistance development.